Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SGNB-6A by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
SGNB-6A is under clinical development by Pfizer and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative...
SGNB-6A by Pfizer for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
SGNB-6A is under clinical development by Pfizer and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to...
SGNB-6A by Pfizer for Squamous Cell Carcinoma: Likelihood of Approval
SGNB-6A is under clinical development by Pfizer and currently in Phase I for Squamous Cell Carcinoma. According to GlobalData, Phase...
SGNB-6A by Pfizer for Bladder Cancer: Likelihood of Approval
SGNB-6A is under clinical development by Pfizer and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I...
SGNB-6A by Pfizer for Gastric Cancer: Likelihood of Approval
SGNB-6A is under clinical development by Pfizer and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
SGNB-6A by Pfizer for Cervical Cancer: Likelihood of Approval
SGNB-6A is under clinical development by Pfizer and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
SGNB-6A by Pfizer for Ovarian Cancer: Likelihood of Approval
SGNB-6A is under clinical development by Pfizer and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...